RESUMEN
Bevacizumab plus platinum-based chemotherapy provides modest benefits in non-squamous non-small cell lung cancer (NSCLC), while its application as a neoadjuvant regimen has yet to be validated. The present study aimed to assess the efficacy of neoadjuvant bevacizumab plus platinum-based chemotherapy in patients with stage-IIIA non-squamous NSCLC. Data from 110 patients with stage-IIIA non-squamous NSCLC with negative driver genes, who received neoadjuvant bevacizumab plus platinum-based chemotherapy (n=50) or neoadjuvant platinum-based chemotherapy alone (n=60), and tumor resection, were retrospectively reviewed in the current study. In addition, the data on pathological response, disease-free survival (DFS), overall survival (OS) and adverse events were obtained. The results demonstrated that neoadjuvant bevacizumab plus chemotherapy did not significantly increase the pathological complete response (pCR) rate in comparison with neoadjuvant chemotherapy alone (18.0 vs. 8.3%; P=0.130). However, neoadjuvant bevacizumab plus chemotherapy significantly increased the rates of DFS (P=0.007) and OS (P=0.049) compared with neoadjuvant chemotherapy alone. Adjustments were then performed using multivariate logistic or Cox regression analyses, which demonstrated that neoadjuvant bevacizumab plus chemotherapy in comparison with neoadjuvant chemotherapy alone only significantly independently prolonged DFS [hazard ratio (HR)=0.251; P=0.042], but did not significantly affect pCR (odds ratio=2.897; P=0.117) or OS (HR=0.297; P=0.158). Furthermore, no significant differences were demonstrated between the number of adverse events in patients receiving neoadjuvant bevacizumab plus chemotherapy in comparison with those receiving neoadjuvant chemotherapy alone (all P>0.05). In conclusion, neoadjuvant bevacizumab plus platinum-based chemotherapy was only associated with a significant improvement in the rate of DFS, but showed limited efficacy in improving pCR and OS rates in comparison with neoadjuvant chemotherapy alone in patients with stage-IIIA non-squamous NSCLC. Therefore, a larger sample size and randomized controlled studies are needed for further validation of the findings of the present study.
RESUMEN
In this study, we report the complete mitochondrial genomes (mtgenome) of Thyreus decorus, Ceratina okinawana and Amegilla calceifera, which are the first time of mtgenome report also for the genera Thyreus, Ceratina and Amegilla in the family Apidae. They contain 15,237, 15,207, and 17,728 bp, with AT content of 84.97%, 79.30%, and 84.63%, respectively. Each mtgenome includes 13 protein-coding genes (PCGs), 22 transfer RNA (tRNAs), two ribosomal RNA (16S and 12S rRNA) and an AT-rich control region (CR). The phylogenetic relationships of 45 species in the family were constructed using Bayesian Inference based on concatenated nucleotide sequences of 13 PCGs. Our study suggests that the subfamily Apinae is a paraphyletic group, with the genus Eucera claded into the subfamily Xylocopinae and the genera Amegilla and Thyreus into the subfamily Nomadinae. In Apinae, the genera Melipona and Bombus are significantly sister group, and the genus Apis is the sister group with Melipona + Bombus.
RESUMEN
Discoelius brevilamellatus Wang, Chen Li, sp. nov. is described and illustrated from Tibet, China, and Discoelius turneri (Meade-Waldo, 1910) is newly recorded from China.
